Niagen Bioscience Q1 sales up 3% to $31.5M; net income helped by $4.8M divestiture gain
Niagen Bioscience reported first-quarter 2026 net sales of $31.5 million, up 3% from a year earlier, and net income of $6.3 million, up from $5.1 million. Net income includes a $4.8 million gain on the sale of its Analytical Reference Standards and Services segment, while operating income fell to $1.6 million from $4.8 million and adjusted EBITDA fell to $3.8 million from $4.9 million, so shareholders should weigh the one-time gain against weaker core profitability.
Key points
- Net sales rose 3% to $31.5 million; excluding the divested segment in both periods, sales rose about 5%.
- Operating expenses increased 26% to $18.4 million, and operating income fell to $1.6 million from $4.8 million.
- Operating cash flow was a $1.2 million outflow, and cash and cash equivalents ended at $66.5 million.
- For 2026, the company expects net sales to grow 10% to 15% excluding the divested segment, and general and administrative expense to rise $3 million to $4 million.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.